Financial Daily from THE HINDU group of publications
Friday, Jul 12, 2002

News
Features
Stocks
Port Info
Archives

Group Sites

Corporate - Restructuring


Dabur moves a step towards demerger — Separates pharma, FMCG businesses

Our Bureau

NEW DELHI, July 11

AS a precursor to hiving off the company's pharma business into a separate entity, Dabur India Ltd today announced the "virtual demerger" of its FMCG business from its pharma business.

"Dabur India has restructured its Rs 162.9-crore pharma business and has virtually separated it from its FMCG business," a company statement issued here today informed. This restructuring was a prelude to spinning off the Dabur's pharma business into a separate outfit at a later date, the note added.

Dabur India's Chairman Mr V.C. Burman had indicated this to Business Line at an interview earlier this year : "Dabur would not be averse to spinning off the pharma division into an independent company, provided the business achieves a critical mass."

The restructuring of Dabur's pharma business plays itself out in that it would continue under the ambit of Dabur India, but would function as a separate business unit internally, under a different head and functional heads. It would also maintain separate books of accounts, the note informed.

The pharma business would be led by the Pharma Management Committee headed by Dr Anand Burman, Vice-Chairman, Dabur India. The committee would determine operational policies and conduct business performance reviews to ensure adequate internal control and standard operating procedures in the business.

The decision is based on the recommendations of Accenture that suggested separation of Dabur's pharma and FMCG businesses to provide greater focus and growth to each business under separate business heads.

The businesses that have been brought under Dabur Pharmaceuticals include the pharma-related activities done by Dabur Research Foundation, Dabur Oncology Plc and Dabur's bulk and formulations businesses.

A `strategy group' has been set up under Dr Anand Burman, to lead the business activities of Dabur Pharmaceuticals.

The strategy group comprises representatives from Dabur India and Dabur Oncology Plc and would be responsible for the formulation of strategy, for the short and long term, for the organisation at a global level.

Dabur's pharma business registered a 7.2 per cent growth, clocking a sales turnover of Rs 162.9 crore for the fiscal ended March 2002.

Send this article to Friends by E-Mail

Stories in this Section
Ranbaxy files application for IV form of Ranbezolid


Amadeus firms up plan to raise market share
Oriental Hotels to pay 45 pc
Apollo Hospitals launches package for diabetics
Can President Bush afford to talk tough?
Dabur moves a step towards demerger — Separates pharma, FMCG businesses
`Corporate governance ratings can curb frauds'
DCA Secy seeks changes in Companies Act
Raunaq Plastics sets up facility near Kolkata
JB Chemicals to set up unit for `Doktor Mom'
Samir Biswas takes over at DCA
Kores India ties up with Brother Intl
Electrolux rights issue runs into rough weather — Company mulling other plans
Lakshmi Synthetic looking down the barrel
LML hopes Freedom will drive it into the black
West Coast Paper plans growth thru acquisitions
Kinetic Intl to be formed in two months
LG Elec registers 42 pc rise in turnover in H1


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |

Copyright 2002, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line